Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$610 Mln
P/E Ratio
34.1
P/B Ratio
1.36
Industry P/E
--
Debt to Equity
0.06
ROE
0.04 %
ROCE
4.11 %
Div. Yield
0 %
Book Value
15.72
EPS
0.63
CFO
$-68.42 Mln
EBITDA
$-183.67 Mln
Net Profit
$-179.64 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Castle Biosciences (CSTL)
| -18.20 | 6.24 | -18.11 | 11.17 | -1.64 | -4.78 | -- |
|
BSE Sensex
| 2.39 | 4.18 | 4.86 | 8.78 | 11.89 | 20.62 | 11.13 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
|
|---|---|---|---|---|---|
|
Castle Biosciences (CSTL)
| 23.28 | -8.33 | -45.09 | -36.16 | 95.37 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 15.65 | 10,289.47 | 14.38 | 12.69 | |
| 72.28 | 9,544.04 | 92.52 | 2.52 | |
| 278.44 | 10,728.90 | 773.26 | 1.2 | |
| 117.67 | 14,455.82 | 41.45 | 5.44 |
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), uveal melanoma, and mental health conditions. The company offers... DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a risk stratification spatial-omics test to predict future development of progression of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide optimal drug treatment for patients diagnosed with major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. The company offers its products to skin cancer and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas. Address: 505 S. Friendswood Drive, Friendswood, TX, United States, 77546 Read more
Founder, CEO, President & Director
Mr. Derek J. Maetzold
Founder, CEO, President & Director
Mr. Derek J. Maetzold
Headquarters
Friendswood, TX
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Castle Biosciences Inc (CSTL) stood at $ 531 Mln as on 31-Dec-24
The share price of Castle Biosciences Inc (CSTL) is $21.80 (NASDAQ) as of 23-Apr-2025 14:39 EDT. Castle Biosciences Inc (CSTL) has given a return of -1.64% in the last 3 years.
Castle Biosciences Inc (CSTL) has a market capitalisation of $ 610 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/E ratio of Castle Biosciences Inc (CSTL) is 34.10 times as on 22-Apr-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Castle Biosciences Inc (CSTL) and enter the required number of quantities and click on buy to purchase the shares of Castle Biosciences Inc (CSTL).
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), uveal melanoma, and mental health conditions. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a risk stratification spatial-omics test to predict future development of progression of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide optimal drug treatment for patients diagnosed with major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. The company offers its products to skin cancer and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas. Address: 505 S. Friendswood Drive, Friendswood, TX, United States, 77546
The CEO & director of Mr. Derek J. Maetzold. is Castle Biosciences Inc (CSTL), and CFO & Sr. VP is Mr. Derek J. Maetzold.
There is no promoter pledging in Castle Biosciences Inc (CSTL).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,126
|
|
|
1,070
|
|
|
1,049
|
|
|
978
|
| Castle Biosciences Inc. (CSTL) | Ratios |
|---|---|
|
Return on equity(%)
|
4.31
|
|
Operating margin(%)
|
6.67
|
|
Net Margin(%)
|
5.49
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Castle Biosciences Inc (CSTL) was $0 Mln.
$-0.18
(
